JSPR May 2024 35.000 call
| Previous close | 1.8500 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 5.0000 |
| Strike | 35.00 |
| Expiry date | 2024-05-17 |
| Day's range | 1.8500 - 1.8500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswireJasper Therapeutics to Present at Upcoming Investor Conferences in May
REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the following upcoming investor conferences in May: Capital One Securities Biotech/Biopharma Disruptors Even
- GlobeNewswire
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the 23rd Annual Needham Virtual Healthcare Conference at 11am EDT on April 8, 2024. A live webcast of the
- GlobeNewswire
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
